Related Experiment Videos
[Serum liver tests in patients treated with methotrexate. A retrospective analysis]
Hernán Correa G1, Natalia Paredes S
1Servicio de Dermatología, Hospital Sótero del Río, Chile. hcorreag@uc.cl
Background:
Methotrexate is one of the best systemic treatments for psoriasis. However it has significant adverse effects such as myelotoxicity and hepatotoxicity.
Aim:
To evaluate serum liver test in psoriatic patients treated with methotrexate.
Material And Methods:
Retrospective review of medical records of psoriatic patients treated with methotrexate between the years 2000 and 2005. All patients received a minimum of 7.5 mg weekly of methotrexate, for at least 4 weeks.
Results:
Sixty three patients were included. Mean cumulative dose of methotrexate was 576 mg. Thirty two percent had alterations in liver tests, but only 9% had values that duplicated the upper limit of normal range of aminotransferases or alkaline phosphatases or a serum bilirubin over 2 mg/dl. We did not find a direct relationship between the dose of methotrexate and the magnitude of liver test alterations. Only one patient exceeded 1.5 g as cumulative dose. A liver biopsy performed to him, did not show signs of fibrosis.
Conclusions:
This retrospective study does not show a direct relationship between weekly doses, cumulated dose and length of treatment with methotrexate, and the degree of alteration of serum liver tests.
Related Concept Videos
Therapeutic Drug Monitoring: Affecting Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Serum Studies: Renal Function Tests
Therapeutic Drug Monitoring: Drug Analysis Methods
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase